Aditya Kohli

Aditya Kohli is a Partner at Frazier Life Sciences, where he invests in life sciences across biopharmaceuticals and biotechnology, including therapeutics, oncology, autoimmune disorders, vaccines, dermatology, and gastrointestinal. He invests from company creation through early- and late-stage private rounds (including Series B) as well as in public companies (small and mid-cap). He invests globally, including in the United States and the United Kingdom. Frazier Life Sciences raised $1.3 billion in July 2025. He has invested in companies like HilleVax, Phathom Pharmaceuticals, and Scout Bio, and has served on the boards of HilleVax and Scout Bio. Before his current role, he was Venture Partner, Principal, Vice President, and Senior Associate at Frazier Life Sciences; Chief Business Officer & Co-founder at Phathom Pharmaceuticals; CBO & Co‑Founder, COO & Co‑Founder, and Board Director at HilleVax; and Board Director & Co‑founder at Scout Bio. Earlier, he was an Associate and Engagement Manager at McKinsey & Company. Aditya studied at the Massachusetts Institute of Technology, the University of California, Berkeley, and the University of California, San Francisco, and lives in New York.